Shots:
- Apellis & Sobi have reported data from the open-label period of P-III (VALIANT) trial of Empaveli for the treatment of C3G & primary immune complex membranoproliferative glomerulonephritis (IC-MPGN); regulatory review is ongoing in the US & EU
- The P-III (VALIANT) trial assessed Empaveli (Q2W) vs PBO in C3G or primary IC-MPGN pts (≥12yrs., n=124) for 26wks. followed by 26wk. open-label period, where all pts received Empaveli
- Trial showed a 68% proteinuria reduction at Wk. 26, sustained through 1yr., with stabilized kidney function per eGFR; pts who switched to Empaveli after 26wks. of treatment period showed similar benefits across proteinuria levels & kidney function. Data was presented at ERA 2025
Ref: GlobeNewswire | Image: Apellis Pharmaceuticals and Sobi| Press Release
Related News:- Scientist.com Launches Clinical Labs Navigator to Improve Clinical Trial Operations
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
